Santhera Pharma Partners With Ikris Pharma To Launch AGAMREE In India For DMD Treatment

Santhera Pharmaceuticals (SANN.SW) has entered into an exclusive five-year distribution agreement with Ikris Pharma Network to commercialize AGAMREE (vamorolone) for Duchenne muscular dystrophy (DMD) patients aged four and older in India. Santhera will receive a share of net sales, with initial sales projected to commence in Q4 2025 under a named patient program, furthering the company's global expansion strategy for the therapy.

Analysis

Santhera Pharmaceuticals (SANN.SW) is methodically executing its global commercialization strategy for AGAMREE, its treatment for Duchenne muscular dystrophy (DMD), by securing an exclusive distribution agreement in India with Ikris Pharma Network. This five-year arrangement provides a clear path into a significant emerging market, with Santhera set to receive a share of net sales, mirroring the structure of its previous deals in Turkey and the Gulf Cooperation Council countries. Importantly, the financial impact is not immediate, as initial sales under a named patient program are projected to commence in the fourth quarter of 2025. This timeline provides visibility into a future revenue stream but requires investor patience. The agreement reinforces Santhera's operational progress in expanding access to its rare disease therapy, a key component of its long-term value proposition.

Key Decisions for Investors

• Investors should view this agreement as a positive long-term catalyst that validates Santhera's global commercialization strategy for AGAMREE, but temper near-term expectations as revenue contribution is not expected until late 2025.
• Consider this a de-risking event for the company's international expansion plan; however, it is prudent to monitor for future milestones, such as regulatory progress and the official launch of the named patient program in India.
• The consistent deal structure, based on a share of net sales, adds a degree of predictability to future revenue models, and investors should factor this incremental, long-dated revenue stream into valuation analyses.